Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) and Prime Medicine (NYSE:PRME – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
Institutional and Insider Ownership
56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Comparatively, 23.5% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Achilles Therapeutics and Prime Medicine”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Achilles Therapeutics | N/A | N/A | -$69.67 million | ($1.65) | -0.84 |
| Prime Medicine | N/A | N/A | -$198.13 million | ($2.05) | -1.44 |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Achilles Therapeutics and Prime Medicine, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Achilles Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
| Prime Medicine | 0 | 0 | 9 | 1 | 3.10 |
Achilles Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 189.86%. Prime Medicine has a consensus price target of $13.13, suggesting a potential upside of 343.41%. Given Prime Medicine’s stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Achilles Therapeutics.
Profitability
This table compares Achilles Therapeutics and Prime Medicine’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Achilles Therapeutics | N/A | -54.45% | -47.68% |
| Prime Medicine | N/A | -107.87% | -74.97% |
Risk & Volatility
Achilles Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.
Summary
Prime Medicine beats Achilles Therapeutics on 7 of the 11 factors compared between the two stocks.
About Achilles Therapeutics
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
